Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arne K. Sandvik is active.

Publication


Featured researches published by Arne K. Sandvik.


Regulatory Peptides | 2001

A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control

C. Dornonville de la Cour; Maria Björkqvist; Arne K. Sandvik; Ingunn Bakke; Chun-Mei Zhao; Duan Chen; R. Håkanson

Ghrelin is a 28 a.a. gastric peptide, recently identified as a natural ligand of the growth hormone secretagogue receptor (orphan receptor distinct from the receptor for growth hormone releasing hormone). In the present study, radioimmunoassay demonstrated ghrelin-like material in the rat oxyntic mucosa with moderate amounts also in antrum and duodenum. Small amounts were found in the distal intestines and pancreas. Northern blot analysis revealed abundant ghrelin mRNA in the oxyntic mucosa. Immunocytochemistry demonstrated ghrelin-immunoreactivity in endocrine-like cells in the oxyntic mucosa. Such cells occurred in low numbers also in the antrum and duodenum. The rat oxyntic mucosa is rich in endocrine (chromogranin A/pancreastatin-immunoreactive) cells, such as the histamine-rich ECL cells (65-75% of the endocrine cells), the A-like cells (20-25%) and the D cells (somatostatin cells) (10%). The ghrelin-immunoreactive (IR) cells contained pancreastatin but differed from ECL cells and D cells by being devoid of histamine-forming enzyme (ECL cell constituent) and somatostatin (D cell constituent). Hence, ghrelin seems to occur in the A-like cells. The ghrelin-IR cells in the antrum were distinct from the gastrin cells, the serotonin-containing enterochromaffin cells and the D cells. Conceivably, ghrelin cells in the antrum and distally in the intestines also belong to the A-like cell population. The concentration of ghrelin in the circulation was lowered by about 80% following the surgical removal of the acid-producing part of the stomach in line with the view that the oxyntic mucosa is the major source of ghrelin. The serum ghrelin concentration was higher in fasted rats than in fed rats; it was reduced upon re-feeding and seemed unaffected by 1-week treatment with the proton pump inhibitor omeprazole, resulting in elevated serum gastrin concentration. Infusion of gastrin-17 for 2 days failed to raise the serum ghrelin concentration. Omeprazole treatment for 10 weeks raised the level of HDC mRNA but not that of ghrelin mRNA or somatostatin mRNA in the oxyntic mucosa. Hence, unlike the ECL cells, ghrelin-containing A-like cells do not seem to operate under gastrin control.


Gut | 1996

Marked increase in gastric acid secretory capacity after omeprazole treatment.

Helge L. Waldum; J S Arnestad; E Brenna; I Eide; U Syversen; Arne K. Sandvik

BACKGROUND: In contrast with the histamine2 (H2) blockers, proton pump inhibitors have not been shown to give rebound hypersecretion of acid. Taking into consideration the hyperplasia of the enterochromaffin-like (ECL) cell provoked by hypergastrinaemia secondary to profound acid inhibition and the central role of histamine from ECL cells in the regulation of acid secretion, the lack of any rebound acid hypersecretion after treatment with proton pump inhibitors has been questioned. AIMS: To reassess the effect of treatment with omeprazole on post-treatment acid secretion. METHODS AND PATIENTS: Basal and pentagastrin stimulated acid secretion were determined in nine patients with reflux oesophagitis before and 14 days after termination of a 90 day treatment period with the proton pump inhibitor omeprazole (40 mg daily). Basal gastrin release were determined before and during omeprazole treatment. Furthermore, biopsy samples from the oxyntic mucosa were taken before and at the end of the treatment period for chemical (histamine and chromogranin A (CgA)) evaluation of the ECL cell mass. RESULTS: A substantial increase in meal stimulated gastrin release during omeprazole treatment resulted in an increased ECL cell mass. Furthermore, CgA in serum increased during omeprazole treatment suggesting that serum CgA may be used as a test to evaluate ECL cell hyperplasia. A significant increase in basal and a marked (50%) and significant increase in pentagastrin stimulated acid secretion were found after treatment with omeprazole. CONCLUSIONS: Increased acid secretion after a conventional treatment period with a proton pump inhibitor is probably due to ECL cell hyperplasia and may have negative consequences for acid related diseases.


Scandinavian Journal of Gastroenterology | 1990

The Predictive Value of History in Dyspepsia

Terje Johannessen; Hermod Petersen; P. M. Kleveland; J. H. Dybdahl; Arne K. Sandvik; Eiliv Brenna; Helge L. Waldum

Symptomatic patients referred to an open-access upper gastrointestinal endoscopy completed a detailed, self-administered questionnaire aimed at assessing the predictive value of history in dyspepsia. Nine hundred and thirty patients were suitable for analysis. Of these, 29% were found to have organic dyspepsia. A substantial overlap of symptoms and demographic data was found among the various endoscopic diagnoses. Discriminating variables were identified by stepwise logistic regression analysis and included in predictive score models. Pain relieved by antacids, age above 40 years, previous peptic ulcer disease, male sex, symptoms provoked by berries, and night pain relieved by antacids and food were found to predict organic dyspepsia with a sensitivity and specificity of approximately 70%, when applied on the observed material. Similar probabilities were found for score models of peptic ulcer and esophagitis. In general, the low prevalence of organic diseases resulted in low positive and high negative predictive values. Accordingly, the main impact of the predictive models may be to reduce the number of negative endoscopies rather than to predict a precise diagnosis. Independent of disease category and age, 41% of the subjects expressed a fear of malignancy, emphasizing the value of reassurance from a negative endoscopy.


Journal of Experimental & Clinical Cancer Research | 2008

Classification of tumours

Helge L. Waldum; Arne K. Sandvik; Eiliv Brenna; Reidar Fossmark; Gunnar Qvigstad; Jun Soga

Tumours are classified according to the most differentiated cells with the exception of carcinomas where a few tumour cells show neuroendocrine differentiation. In this case these cells are regarded as redifferentiated tumour cells, and the tumour is not classified as neuroendocrine. However, it is now clear that normal neuroendocrine cells can divide, and that continuous stimulation of such cells results in tumour formation, which during time becomes increasingly malignant. To understand tumourigenesis, it is of utmost importance to recognize the cell of origin of the tumour since knowledge of the growth regulation of that cell may give information about development and thus possible prevention and prophylaxis of the tumour. It may also have implications for the treatment. The successful treatment of gastrointestinal stromal tumours by a tyrosine kinase inhibitor is an example of the importance of a correct cellular classification of a tumour. In the future tumours should not just be classified as for instance adenocarcinomas of an organ, but more precisely as a carcinoma originating from a certain cell type of that organ.


Science Translational Medicine | 2014

Denervation suppresses gastric tumorigenesis.

Chun-Mei Zhao; Yoku Hayakawa; Yosuke Kodama; Sureshkumar Muthupalani; Christoph B. Westphalen; Gøran Andersen; Arnar Flatberg; Helene Johannessen; Richard A. Friedman; Bernhard W. Renz; Arne K. Sandvik; Vidar Beisvag; Hiroyuki Tomita; Akira Hara; Michael Quante; Zhishan Li; Michael D. Gershon; Kazuhiro Kaneko; James G. Fox; Timothy C. Wang; Duan Chen

Surgical or pharmacologic interruption of muscarinic innervation to the stomach suppresses gastric tumor growth in mice and humans. Treating Cancer by Getting on Its Nerves The nervous system plays a role in the regulation of many different organs, including the gut. Now, Zhao et al. have shown that the vagal nerve, which signals to the stomach through muscarinic receptors, contributes to the growth of gastric tumors. The authors demonstrated that vagotomy (surgical interruption of the vagal nerve) can prevent gastric cancer in mice and reduce the recurrence of gastric tumors in human patients. Moreover, the same result can be achieved in mice treated with Botox or anticholinergic drugs to inhibit vagal nerve signaling, raising the hope of a safer treatment for gastric cancer without irreversible side effects. The nervous system plays an important role in the regulation of epithelial homeostasis and has also been postulated to play a role in tumorigenesis. We provide evidence that proper innervation is critical at all stages of gastric tumorigenesis. In three separate mouse models of gastric cancer, surgical or pharmacological denervation of the stomach (bilateral or unilateral truncal vagotomy, or local injection of botulinum toxin type A) markedly reduced tumor incidence and progression, but only in the denervated portion of the stomach. Vagotomy or botulinum toxin type A treatment also enhanced the therapeutic effects of systemic chemotherapy and prolonged survival. Denervation-induced suppression of tumorigenesis was associated with inhibition of Wnt signaling and suppression of stem cell expansion. In gastric organoid cultures, neurons stimulated growth in a Wnt-mediated fashion through cholinergic signaling. Furthermore, pharmacological inhibition or genetic knockout of the muscarinic acetylcholine M3 receptor suppressed gastric tumorigenesis. In gastric cancer patients, tumor stage correlated with neural density and activated Wnt signaling, whereas vagotomy reduced the risk of gastric cancer. Together, our findings suggest that vagal innervation contributes to gastric tumorigenesis via M3 receptor–mediated Wnt signaling in the stem cells, and that denervation might represent a feasible strategy for the control of gastric cancer.


Cancer | 1998

Neuroendocrine Differentiation in Human Gastric Carcinoma

Helge L. Waldum; Steinar Aase; Igor Kvetnoi M.D.; Eiliv Brenna; Arne K. Sandvik; Unni Syversen; Gjermund Johnsen; Lars J. Vatten; Julia M. Polak

Distinguishing between neuroendocrine carcinoma and adenocarcinoma may be difficult.


Life Sciences | 1996

Long-term effects of inhaled nicotine

Helge L. Waldum; Odd G. Nilsen; Turid Nilsen; Hege Rørvik; Unni Syversen; Arne K. Sandvik; Olav A. Haugen; Sverre Helge Torp; Eiliv Brenna

Tobacco smoking has been reported to be associated with increased risk of cardiovascular disease and cancer, particularly of the lungs. In spite of extensive research on the health effects of tobacco smoking, the substances in tobacco smoke exerting these negative health effects are not completely known. Nicotine is the substance giving the subjective pleasure of smoking as well as inducing addiction. For the first time we report the effect on the rat of long-term (two years) inhalation of nicotine. The rats breathed in a chamber with nicotine at a concentration giving twice the plasma concentration found in heavy smokers. Nicotine was given for 20 h a day, five days a week during a two-year period. We could not find any increase in mortality, in atherosclerosis or frequency of tumors in these rats compared with controls. Particularly, there was no microscopic or macroscopic lung tumors nor any increase in pulmonary neuroendocrine cells. Throughout the study, however, the body weight of the nicotine exposed rats was reduced as compared with controls. In conclusion, our study does not indicate any harmful effect of nicotine when given in its pure form by inhalation.


pacific symposium on biocomputing | 2000

Predicting gene function from gene expressions and ontologies.

Torgeir R. Hvidsten; Jan Komorowski; Arne K. Sandvik; Astrid Lægreid

We introduce a methodology for inducing predictive rule models for functional classification of gene expressions from microarray hybridisation experiments. The basic learning method is the rough set framework for rule induction. The methodology is different from the commonly used unsupervised clustering approaches in that it exploits background knowledge of gene function in a supervised manner. Genes are annotated using Ashburners Gene Ontology and the functional classes used for learning are mined from these annotations. From the original expression data, we extract a set of biologically meaningful features that are used for learning. A rule model is induced from the data described in terms of these features. Its predictive quality is fine-turned via cross-validation on subsets of the known genes prior to classification of unknown genes. The predictive and descriptive quality of such a rule model is demonstrated on the fibroblast serum response data previously analysed by Iyer et. al. Our analysis shows that the rules are capable of representing the complex relationship between gene expressions and function, and that it is possible to put forward high quality hypotheses about the function of unknown genes.


Alimentary Pharmacology & Therapeutics | 1997

Review article: the pharmacological inhibition of gastric acid secretion—tolerance and rebound

Arne K. Sandvik; Eiliv Brenna; Helge L. Waldum

During the last decade our understanding of the regulation of gastric acid secretion has changed considerably. The recognition that gastrin acts mainly by releasing histamine from the enterochromaffin‐like (ECL) cell is of major importance. It is now necessary to review and seek new explanations for the development of tolerance and for the post‐treatment acid hypersecretion that may be observed when treatment with acid‐secretory inhibitors is discontinued. Tolerance and rebound related to H2‐receptor antagonists has previously been explained as upregulation of gastrin and/or histamine H2‐receptors, and/or an increased parietal cell mass. Experimental evidence for these theories is scarce. On the other hand, tolerance can now be explained by a gastrin‐induced increase in ECL cell‐derived histamine at the parietal cell H2‐receptor competing with the antagonist. The lack of tolerance to proton pump inhibitors may be explained by their mode of action, being non‐competitive and acting at the H+, K+‐ATPase rather than at stimulatory receptors. Post‐treatment rebound acid hypersecretion can be understood as gastrin upregulating and/or stimulating growth of the ECL cell, leading to increased amounts of releasable histamine post‐treatment. Novel experimental data strongly support this view of the development of tolerance and post‐treatment rebound acid hypersecretion.


Scandinavian Journal of Gastroenterology | 2004

Treatment of ECL cell carcinoids with octreotide LAR

Vidar Fykse; Arne K. Sandvik; Gunnar Qvigstad; Sture Falkmer; Unni Syversen; Helge L. Waldum

Background: Patients with chronic atrophic gastritis (CAG) and hypergastrinaemia are at risk of developing hyperplasia of the enterochromaffin‐like (ECL) cells and ECL‐cell‐derived tumours. The effect of the somatostatin analogue octreotide on ECL cell carcinoids is examined. Methods: Five patients with hypergastrinaemia and ECL cell carcinoids were enrolled in a 1‐year study of octreotide LAR (long‐acting release) 20 mg given at monthly intervals. Biopsies from tumours and from flat oxyntic mucosa were done at the start and 3, 6 and 12 months thereafter. Sections were stained with haematoxylin‐erythrosin, immunostained with chromogranin A (CgA) and doublestained with CgA and Ki‐67. Serum gastrin and CgA were measured. Results: The number of visible tumours was reduced by more than 50 %. Sections from both tumours and flat mucosa showed a reduced number of CgA immunoreactive cells. Mean serum gastrin decreased from 421 to 186 pM (normal <40 pM); P > 0.05, and serum CgA from 73 to 25 ng/ml (normal <30 ng/ml); P < 0.001. Conclusions: During treatment the patients were still markedly hypergastrinaemic, whereas the serum CgA showed normalization. A diminished tumour load and reduced ECL cell density were found, indicating an antiproliferative effect of octreotide directly on the ECL cells.

Collaboration


Dive into the Arne K. Sandvik's collaboration.

Top Co-Authors

Avatar

Helge L. Waldum

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Vidar Beisvag

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Eiliv Brenna

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Ingunn Bakke

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Arnar Flatberg

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Atle van Beelen Granlund

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Gunnar Qvigstad

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Astrid Lægreid

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Reidar Fossmark

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Torunn Bruland

Norwegian University of Science and Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge